United States — Centers for Disease Control and Prevention & Regeneron Pharmaceuticals

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention is assisting in the safe withdrawal of affected Americans, deploying experts to Africa, and monitoring the outbreak while emphasizing the low risk to the United States.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

United States — Centers for Disease Control and Prevention: United States — Centers for Disease Control and Prevention is partnering with the World Health Organization and authorities in the Democratic Republic of the Congo and Uganda to design and implement clinical trials.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention>>> declared the Ebola outbreak a Public Health Emergency of Continental Security, emphasizing the urgency of coordinated action and mobilizing resources for response and preparedness.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.